UNSPSC 51124503: Glimepiride

This classification denotes an anti-diabetic agent with the molecular formula C24H34N4O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 6KY687524K, chemically known as 3-ethyl-n,n-bis(3-ethyl-4-methyl-2-oxo-5h-pyrrol-2-yl)-4-methyl-2-oxo-5h-pyrrole-1-carboxamide but more generally known as glimepiride, which bears US NIH Compound Identifier 3476. European Medicines Agency schedules Glimepiride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07925MIG.

UNSPSC 51124503 Glimepiride is a Commodity code that represents a specific pharmaceutical product—in this case, a diabetes medication—that state and local governments procure through health agencies, emergency medical services, and cooperative purchasing vehicles. Recent activity shows state and local buyers sourcing glimepiride and related medications through emergency medical services procurement, state pharmacy benefit programs, and multistate cooperative contracts. The code does not appear as a standalone line item in recent public solicitations; instead, glimepiride would typically be procured as part of broader medication supply contracts, such as those for advanced life support medications or generic multi-source pharmaceutical programs that include multiple active pharmaceutical ingredients.

State and local procurement under pharmaceutical commodity codes engages city and county emergency services, state health and human services agencies, and multistate cooperative purchasing alliances. The City of Tampa Fire Rescue procured advanced life support medications via IFB (Solicitation 26P00188, due April 8, 2026, with estimated value $40,000) that would likely include diabetes and cardiac medications alongside epinephrine and adenosine; the Texas Health and Human Services Commission issued an RFI (HHS0017013, April 3, 2026) exploring direct-to-manufacturer prescription programs for state pharmacy benefit management; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon. Glimepiride procurement activity concentrates in state pharmacy benefit programs and cooperative purchasing vehicles rather than isolated emergency services contracts. Opportunities tend to flow through established wholesaler networks—AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson in the MMCAP vehicle—with manufacturers competing on fixed or net-price models and administrative compliance rather than individual drug bids.